| Phase 3 trials of novel drug show functional cure in 20% of chronic hepatitis B patients |
| Friday, May 29, 2026 12:31 PM |
| Two replicate phase 3 randomized controlled trials involving patients with chronic hepatitis B virus (HBV) infection demonstrate a functional cure after the discontinuation of conventional long-term antiviral therapy in about 20% of patients given the drug bepirovirsen. Read more. |